Interleukin-12: Murine models of a potent antitumor agent

Annals of the New York Academy of Sciences

Volumn 795, Issue , 1996, Pages 266-274

  Brunda, Michael J ^a   Luistro, Leopoldo ^a   Rumennik, Leonid ^a   Wright, Rosemary B ^a   Wigginton, Jon M ^b   Wiltrout, Robert H ^c   Hendrzak, Jill A ^a   Palleroni, Alicia V ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 2; NITRIC OXIDE; PACLITAXEL; RECOMBINANT INTERLEUKIN 12;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; FIBROBLAST; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; RETICULOSARCOMA; T LYMPHOCYTE;

EID: 0030479068     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb52676.x     Document Type: Conference Paper

References (48)

1. GUBLER, U., A. O. CHUA, D. S. SCHOENHAUT, C. M. DWYER, W. MCCOMAS, R. MOTYKA, N. NABAVI, A. G. WOLITZKY, P. M. QUINN, P. C. FAMILLETTI & M. K. GATELY. 1991. Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 88: 4143-4417.
2. WOLF, S. F., P. A. TEMPLE, M. KOBAYASHI, D. YOUNG, M. DICIG, L. LOWE, R. DZIALO, L. FITZ, C. FERENZ, R. M. HEWICK, K. KELLEHER, S. H. HERRMANN, S. C. CLARK, L. AZZONI, S. H. CHAN, G. TRINCHIERI & B. PERUSSIA. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146: 3074-3081.
3. HENDRZAK, J. A. & M. J. BRUNDA. 1996. Interferons and other cytokines. In Cancer Drug Discovery. B. A. Teicher, Ed. Marcel Dekker. New York. In press.
4. TRINCHIERI, G. 1994. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008-4027.
5. BRUNDA, M.J. & M. K. GATELY. I995. Interleukin-12: Potential role in cancer therapy. In Important Advances in Oncology 1995. V. T. DeVita, Jr., S. Hellman & S. A. Rosenberg, Eds.: 3-18. Lippincott Company. Philadelphia, PA
6. HENDRZAK, J. A. & M. J. BRUNDA. 1995. Interleukin-12: Biological activity, therapeutic utility and role in disease. Lab. Invest. 72: 619-637.
7. SCHOENHAUT, D. S., A. O. CHUA, A. G. WOLITZKY, P. M. QUINN, C. M. DWYER, W. MCCOMAS, P. C. FAMILLETTI, M. K. GATELY & U. GUBLER. 1992. Cloning and expression of murine IL-12. J. Immunol. 148: 3433-3440.
8. GATELY, M. K., A. G. WOLITZKY, P. M. QUINN & R. CHIZZONITE. 1992. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol. 143: 127-142.
9. + NK cells. J. Immunol. 148: 2429-2436.
10. SOIFFER, R. J., M. J. ROBERTSON, C. MURRAY, K. COCHRAN & J. RITZ. 1993. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 82: 2790-2796.
11. BIGDA, J., J. MYSLIWSKA, R. DZIADZIUSZKO, J. BIGDA, A. MYSLIWSKI & A. HELLMANN. 1993. Interleukin 12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia. Leuk. Lymphoma 10: 121-125.
12. ROOK, A. H., M. KUBIN, M. CASSIN, E. C. VONDERHEID, B. R. VOWELS, J. T. WOLFE, S. F. WOLF, A. SINGH, G. TRINCHIERI & S. R. LESSIN. 1995. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J. Immunol. 154: 1491-1498.
13. CESANO, A., S. VISONNEAU, L. CIOE, S. C. CLARK, G. ROVERA & D. SANTOLI. 1994. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest. 94: 1076-1084.
14. CESANO, A., S. VISONNEAU & D. SANTOLI. 1995. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. Cancer Res. 55: 96-101.
15. HILL, L. L., B. PERUSSIA, P. A. MCCUE & R. KORNGOLD. 1994. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res. 54: 763-770.
16. BRUNDA, M. J., L. LUISTRO, R. R. WARRIER, R. B. WRIGHT, B. R. HUBBARD, M. MURPHY, S. F. WOLF & M. K. GATELY. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223-1230.
17. NASTALA, C. L., H. D. EDINGTON, T. G. MCKINNEY, H. TAHARA, M. A. NALESNIK, M. J. BRUNDA, M. K. GATELY, S. F. WOLF, R. D. SCHREIBER, W. J. STORKUS & M. T. LOTZE. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153: 1697-1706.
18. STERN, L. L., C. M. TARBY, B. TAMBORINI & G. A. TRUITT. 1993. Preclinical development of IL-12 as an anticancer drug: Comparison to IL-2. Proc. Am. Assoc. Cancer Res. 34: 520.
19. VOEST, E. E., B. M. KENYON, G. A. TRUITT, M. S. O'REILLY, R. J. D'AMATO & J. FOLKMAN. 1995. Interleukin 12 inhibits angiogenesis in vivo. J. Natl. Cancer Inst. 87: 581-586.
20. MU, J., J.-P. ZOU, N. YAMAMOTO, T. TSUTSUI, X.-G. TAI, M. KOBAYASHI, S. HERRMANN, H. FUJIWARA & T. HAMAOKA. 1995. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 55: 4404-4408.
21. NOGUICHI, Y., E. C. RICHARDS, Y.-T. CHEN & L. J. OLD. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92: 2219-2223.
22. GATELY, M. K. & M. J. BRUNDA. 1995. Interleukin-12: A pivotal regulator of cell-mediated immunity. In Cytokines: Interleukins and their receptors. R. Kurzrock & M. Talpaz, Eds.: 341-366. Kluwer Academic Publishers. Norwell, MA.
23. ZOU, J.-P., N. YAMAMOTO, T. FUJII, H. TAKENAKA, M. KOBAYASHI, S. H. HERRMANN, S. F. WOLF, H. FUJIWARA & T. HAMAOKA. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Intl. Immunol. 7: 1135-1145.
24. O'TOOLE, M., S. F. WOLF, C. O'BRIEN, B. HUBBARD & S. HERRMANN. 1993. EFFECT of in vivo IL-12 administration on murine tumor cell growth. J. Immunol. 150: 294A.
25. VERBIK, D. J., W. W. STINSON, M. J. BRUNDA, A. KESSINGER & S. S. JOSHI. 1995. Therapeutic effects of in vivo administration of interleukin-12 against residual lymphoma. Proc. Am. Assoc. Cancer Res. 36: 480.
26. BRUNDA, M. J., L. LUISTRO, J. A. HENDRZAK, M. FOUNTOULAKIS, G. GAROTTA & M. K. GATELY. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17: 71-77.
27. WIGGINTON, J. M., K. L. KOMSCHLIES, T. C. BACK, J. L. FRANCO, M. J. BRUNDA & R. H. WILTROUT. 1996. Rapid and complete eradication of murine renal carcinoma by administration of interleukin-12 with pulse interleukin-2. J. Natl. Cancer Inst. 88: 38-43.
28. MIKI, S., D. BRADLEY & B. KSANDER. 1995. IL-12 abrogates immune privilege in the anterior chamber of the eye. Reg. Immunol. 6: 186-190.
29. HEGDE, S. P., J. J. BRIGHT, S. KAUSALYA & A. KHAR. 1995. AK-5 tumor-induced expression of interleukin-12: Role of IL-12 in NK-mediated AK-5 regression. Cell. Immunol. 162: 241-247.
30. GATELY, M. K., U. GUBLER, M. J. BRUNDA, R. R. NADEAU, T. D. ANDERSON, J. M. LIPMAN & U. SARMIENTO. 1994. Interleukin-12: A cytokine with therapeutic potential in oncology and infectious diseases. Ther. Immunol. 1: 187-196.
31. TAHARA, H., H. J. ZEH, W. J. STORKUS, I. PAPPO, S. C. WATKINS, U. GUBLER, S. F. WOLF, P. D. ROBBINS & M. T. LOTZE. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182-189.
32. ZITVOGEL, L., H. TAHARA, P. D. ROBINS, W. J. STORKUS, M. R. CLARKE, M. A. NALESNIK & M. T. LOTZE. 1995. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155: 1393-1403.
33. MARTINOTTI, A., A. STOPPACCIARO, M. VAGLIANI, C. MELANI, F. SPREAFICO, M. WYSOCKA, G. PARMIANI, G. TRINCHIERI & M. P. COLOMBO. 1995. CD4 T cells inhibit in vivo the CDS-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25: 137-146.
34. TAHARA, H., L. ZITOVOGEL, W. J. STORKUS, H. J. ZEH, III, T. G. MCKINNEY, R. D. SCHREIBER, U. GUBLER, P. D. ROBBINS & M. T. LOTZE. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154: 6466-6474.
35. KUBIN, M., M. KAMOUN & G. TRINCHIERI. 1994. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180: 211-222.
36. MURPHY, E. E., G. TERRES, S. E. MACATONIA, C.-S. HSIEH, J. MATTSON, L. LANIER, M. WYSOCKA, G. TRINCHIERI, K. MURPHY & A. O'GARRA. 1994. B7 and interleukin 12 cooperate for proliferation and interferon y production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 180: 223-231.
37. ZITVOGEL L. & M. T. LOTZE. 1995. Role of interleukin-12 (IL-12) as an antitumor agent: Experimental biology and clinical application. Res. Immunol. 146: 628-638.
38. DESAI, B. B., P. M. QUINN, A. G. WOLITZKY, P. K. A. MONGINI, R. CHIZZONITE & M. K. GATELY. 1992. IL-12 receptor. II. Distribution and regulation of receptor expression. J. Immunol. 148: 3125-3132.
39. DESAI, B. B., T. TRUITT, S. HONASOGE, R. WARRIER, R. CHIZZONITE & M. K. GATELY. 1993. Expression of functional IL-12R on a human IL-2-dependent T cell line. J. Immunol. 150: 207A.
40. HISCOX, S., M. B. HALLETT, M. C. A. PUNTIS & W. G. JIANG. 1995. Inhibition of cancer cell motility and invasion by interleukin-12. Clin. Exp. Metastasis 13:877-889.
41. BRUNDA, M. J. & M. K. GATELY. 1994. Anti-tumor activity of interleukin-12. Clin. Immunol. Immunopathol. 71: 253-255.
42. TANNENBAUM, C. S., N. WICKER, R. TUBBS, T. OLENKI, J. FINKE, R. BUKOWSKI, & T. A. HAMILTON. 1995. Patterns of chemokine expression and leukocyte infiltration in murine models of cytokine immunotherapy. Proc. Am. Assoc. Cancer Res. 36:495.
43. GATELY, M. K., R. R. WARRIER, S. HONASOGE, D. M. CARVAJAL, D. A. FAHERTY, S. E. CONNAUGHTON, T. D. ANDERSON, U. SARMIENTO, B. R. HUBBARD & M. MURPHY. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Intl. Immunol. 6: 157-167.
44. FUJIWARA, H., J.-P. ZOU, S. HERRMANN &T. HAMAOKA. 1995. A sequence of cellular and molecular events involved in IL-12-induced tumour regression. Res. Immunol. 146: 638-644.
45. DALTON, D. K., S. PITTS-MEEK, S. KESHAV, I. S. FIGARI, A. BRADLEY & T. A. STEWART. 1993. Multiple defects of immune cell function in mice with disrupted interferon-y genes. Science 259: 1739-1742.
46. BRUNDA, M. J., L. LUISTRO, R. WARRIER & M. K. GATELY. 1995. Antitumor activity of interleukin-12 compared to and combined with other cytokines. Proc. Ninth Intl. Congress Immunol. American Association of Immunology, Bethesda, MD, p. 871.
47. EMI, Y., G. ARA, S. A. HOLDEN, S. CLINTON & B. A. TEICHER. 1995. Interleukin12 (IL-12) enhances antitumor activity of chemotherapy and radiotherapy in murine models. Proc. Am. Assoc. Cancer Res. 36: 480.
48. SKLADANOWSKI, A. & J. KONOPA. 1993. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 46: 375-382.